close

Fundraisings and IPOs

Date: 2017-10-17

Type of information: Series A financing round

Company: Gemini therapeutics (USA - MA)

Investors: Atlas Venture (USA-MA) Lightstone Ventures (USA-CA) OrbiMed (USA-NY)

Amount: $42.5 Million

Funding type: series A financing round

Planned used:

  • These funds will be used to  to advance multiple programs into the clinic. Gemini is developing first-in-class therapeutics built on the strong foundation of human genetics research in AMD, the leading cause of irreversible blindness in the U.S. and EU. The company has developped a multimodal pipeline that includes monoclonal antibodies, recombinant proteins and gene therapies.

Others:

  • • On October 17, 2017, Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases,  announced that it has completed a $42.5 million Series A financing to advance multiple programs into the clinic. Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, and also invested in seed financing in 2016. The company’s scientific founders include the University of Edinburgh’s Paul Barlow, Ph.D., and Andy Herbert, Ph.D., and Tufts University’s Johanna Seddon, M.D., M.Sc. Gemini’s scientific advisory board is comprised of: Retinal disease and AMD experts including, Alan Wright, Ph.D., M.B. Ch.B., from the University of Edinburgh, Napoleone Ferrara, M.D. from the University of California San Diego, Dean Bok, Ph.D., from University of California Los Angeles, and Bruce Jaffee, Ph.D. Target Biology experts including John Atkinson, M.D., from Washington University in St. Louis, Michael Ehrmann, Ph.D., from the University of Essen-Duisberg, Kevin Marchbank, Ph.D., and Claire Harris Ph.D., from Newcastle University, and Simon Clark Ph.D., from the University of Manchester Gene Therapy experts including Shannon Boye, Ph.D., from the University of Florida, Aravind Asokan, Ph.D., from the University of North Carolina, and Chris Mueller, Ph.D., M.Sc., and Claudio Punzo, Ph.D., from the University of Massachusetts Medical School.
  • In addition to Mr. McLaughlin, Gemini’s board of directors includes leading life science investors and biotech leaders: Jean George, General Partner at Lightstone Ventures Carl Gordon, Ph.D., CFA, General Partner at OrbiMed Phil Reilly, M.D., J.D., Independent Board Member and Venture Partner at Third Rock Ventures Jason Rhodes, General Partner at Atlas Venture Steve Squinto, Ph.D., Independent Board Member and Venture Partner at OrbiMed Advisors

Therapeutic area: Rare diseases - Genetic diseases- Ophthalmological diseases

Is general: Yes